Lv4
554 积分 2021-11-10 加入
The role of digital tools and artificial intelligence in supporting antimicrobial stewardship: a systematic review
2天前
已完结
Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the International Organization for the Study of IBD
11天前
已完结
A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab
11天前
已完结
Blocking the gut-liver IgA axis attenuates macrophage-mediated inflammation and injury in alcohol-associated liver disease
1个月前
已完结
Efficacy and Safety of Vedolizumab and Tofacitinib (VETO) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti-TNF and a Second-Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial
1个月前
已完结
Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial
1个月前
已完结
Association of White Blood Cell Count with Treatment Response to Cefepime vs Piperacillin-Tazobactam
2个月前
已完结
[Chinese guideline for the chemotherapy of multidrug-resistant/rifampicin-resistant tuberculosis (2026 edition)]
2个月前
已完结
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
2个月前
已完结
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
2个月前
已完结
皖公网安备34019202002308
